Five things to know:
1. Medtronic’s spine line reported a 0.9 percent revenue increase to $658 million for the first quarter. When combined with Medtronic’s spine and enabling technologies sales — which includes spinal robotics and navigation — global spine and U.S. core spine revenues grew in the mid-single digits.
2. Cervical spine sales were up in the mid-single digits, largely attributed to the Infinity OCT system launch and growth of Prestige LP cervical disc use.
3. Medtronic reported Infuse sales were up in the low double-digits for the quarter, on a constant currency basis.
4. The brain therapies sales, which include the neurosurgery business, reported 9.8 percent revenue growth to $740 million. Double-digit growth of StealthStation S8 surgical navigation systems, O-arm surgical imaging systems and Mazor X robotic guidance system drove the neurosurgery business.
5. Medtronic also reported a 7 percent decrease in pain therapies revenue for the first quarter, which hit $292 million. The company attributed channel destocking and a slowdown in the spinal cord stimulation market for the segment’s poor performance.
More articles on spine devices:
Dr. Abdul Baker performs robotic-assisted spinal surgery at Sanford hospital
Who had the best Q2? How 12 spine, orthopedic companies performed
4 recent spine, orthopedic device company mergers & acquisitions
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
